Journal ArticleDOI
Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets
TLDR
LncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target for the selective killing of cancer cells in patients.Abstract:
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential. Some lncRNAs such as PCA3 is now routinely used in the clinic for the diagnosis of prostate cancer. Single nucleotide polymorphisms (SNPs) in lncRNAs can also be used as a predictor of cancer risk. Although ongoing studies continue to unravel the underlying mechanism, some lncRNAs have been used as therapeutic targets for the selective killing of cancer cells in patients. Thus lncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target. Companies such as the Curna Inc., MiNA Therapeutics Ltd. and RaNA Therapeutics Inc. have been taking steps to develop lncRNA based strategies against cancer. In this review, we discuss the potential of lncRNAs as biomarkers and therapeutic targets in cancer patients.read more
Citations
More filters
Journal ArticleDOI
Biomarkers of gastric cancer: Current topics and future perspective.
Tasuku Matsuoka,Masakazu Yashiro +1 more
TL;DR: The current status and approaches in GC biomarker are summarized, which could be potentially used for early diagnosis, accurate prediction of therapeutic approaches and the future perspective based on the molecular classification and profiling is discussed.
Journal ArticleDOI
LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer
Gang Zhang,Shuwei Li,Jiafei Lu,Yuqiu Ge,Qiaoyan Wang,Gaoxiang Ma,Qinghong Zhao,Dongdong Wu,Weida Gong,Mulong Du,Haiyan Chu,Meilin Wang,Aihua Zhang,Zhengdong Zhang +13 more
TL;DR: MT1JP, a down-regulated lncRNA in GC, was associated with malignant tumor phenotypes and survival of GC, and it is suggested that MT1JP may act as a potential therapeutic target and prognosis biomarker for GC.
Journal ArticleDOI
Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.
Shruti Mishra,Sumit Singh Verma,Vipin Rai,Nikee Awasthee,Srinivas Chava,Kam M. Hui,Alan Prem Kumar,Kishore B. Challagundla,Gautam Sethi,Subash C. Gupta +9 more
TL;DR: How the modulation of lncRNAs by phytochemicals produce therapeutic effects on cancer and other chronic diseases is discussed in this review.
Journal ArticleDOI
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Nicola Amodio,Maria Angelica Stamato,Giada Juli,Eugenio Morelli,Mariateresa Fulciniti,Martina Manzoni,Martina Manzoni,Elisa Taiana,Elisa Taiana,Luca Agnelli,Luca Agnelli,Maria Eugenia Gallo Cantafio,Enrica Romeo,Lavinia Raimondi,Daniele Caracciolo,Valeria Zuccalà,Marco Rossi,Antonino Neri,Antonino Neri,Nikhil C. Munshi,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone,Pierfrancesco Tassone +23 more
TL;DR: A crucial role of MALAT1 in the regulation of the proteasome machinery is demonstrated, and proof-of-concept that its targeting is a novel powerful option for the treatment of MM is provided.
Journal ArticleDOI
Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.
Peixin Dong,Ying Xiong,Junming Yue,Sharon J.B. Hanley,Noriko Kobayashi,Yukiharu Todo,Hidemichi Watari +6 more
TL;DR: The latest insights into the expression pattern, biological roles and mechanisms underlying the function and regulation of NEAT1 in tumors are highlighted, and its clinical implication as a new diagnostic biomarker and an attractive therapeutic target for cancers is focused on.
References
More filters
Journal ArticleDOI
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.
Rohit Malik,Lalit Patel,John R. Prensner,Yang Shi,Matthew K. Iyer,Shruthi Subramaniyan,Alexander Carley,Yashar S. Niknafs,Anirban Sahu,Sumin Han,Teng Ma,Meilan Liu,Irfan A. Asangani,Xiaojun Jing,Xuhong Cao,Saravana M. Dhanasekaran,Dan R. Robinson,Felix Y. Feng,Arul M. Chinnaiyan +18 more
TL;DR: This study identifies PCAT29 as the first androgen receptor–repressed lncRNA that functions as a tumor suppressor in prostate cancer and that its loss may identify a subset of patients at higher risk for disease recurrence.
Journal Article
Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer
Shouping Xu,Shiyao Sui,Jinfeng Zhang,Nan-xia Bai,Qingyu Shi,Guangwen Zhang,Song Gao,Zilong You,Chao Zhan,Feng Liu,Da Pang +10 more
TL;DR: The results indicate for the first time that MALAT1 is a novel regulator of EMT in breast cancer and may be a potential therapeutic target for breast cancer metastasis.
Journal ArticleDOI
Impact of comorbidity, symptoms, and patients' characteristics on the prognosis of oral carcinomas.
TL;DR: Clinical variables have a prognostic impact on oral cancer that is surgically treated, and the consistency of results confirms that survival estimates can be improved by the addition of these elements to the TNM classification, creating a more powerful and precise system in the determination of a prognosis.
Journal ArticleDOI
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression
Marion A. Salvador,Julien Wicinski,Olivier Cabaud,Yves Toiron,Pascal Finetti,Emmanuelle Josselin,Hélène Lelièvre,Laurence Kraus-Berthier,Stéphane Depil,François Bertucci,Yves Collette,Daniel Birnbaum,Emmanuelle Charafe-Jauffret,Christophe Ginestier +13 more
TL;DR: This study identified the long noncoding RNA Xist (X-inactive specific transcript) as a biomarker predicting BCL response to HDACi and validated that low Xist expression predicts drug response in PDXs associated with a significant reduction of the breast CSC population.
Journal ArticleDOI
Polymorphisms in the H19 Gene and the Risk of Bladder Cancer
Gerald W. Verhaegh,Linda Verkleij,Sita H. Vermeulen,Martin den Heijer,J. Alfred Witjes,Lambertus A. Kiemeney +5 more
TL;DR: An SNP polymorphism in the non-protein-encoding H19 gene is associated with a decreased risk of developing non-muscle-invasive bladder cancer.